MEFV

Across TCGA pan-cancer cohorts, MEFV mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MEFV data layer compared with 25 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher MEFV mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MEFV expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

GBM, HNSC, and LUAD are the cancer types where MEFV mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.241	0.816	.024	10	view →
HNSC	OS	Tertile	IV	0.940	0.621	.023	2	view →
LUAD	DFS	Tertile	II,III,IV	1.000	0.742	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MEFV–GBM (OS)

Open the GBM breakdown →